| Bortezomib studied in …STUDIED_INderived200 of 722show all (up to 200) |
|---|
| → studied in | NCT07222761Phase 3 · recruiting A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391657Phase 3 · recruiting A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00092222Phase 2 · active not recruiting Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity · 722 trials list this drug (132 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04181827Phase 3 · active not recruiting A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04722146Phase 1 · active not recruiting A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04133636Phase 2 · active not recruiting A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04923893Phase 3 · active not recruiting A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05083169Phase 3 · active not recruiting A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05623020Phase 3 · recruiting A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06169215Phase 2 · active not recruiting Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06208150Phase 3 · active not recruiting A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06577025Phase 2 · active not recruiting A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07665450Phase 3 · recruiting A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07652905Phase 2 · recruiting CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia · 722 trials list this drug (132 active) | — | — | Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07623798Phase 3 · recruiting A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03004287Phase 2 · active not recruiting 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01971658Phase 3 · completed Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07085728Phase 2 · recruiting Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01861314Phase 1 · active not recruiting Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia · 722 trials list this drug (132 active) | — | — | Secondary Acute Myeloid Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia Post Cytotoxic Therapy+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04915248Phase 2 · recruiting Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. · 722 trials list this drug (132 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05519085Phase 3 · recruiting A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07624513Phase 3 · not yet recruiting D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01695941Phase 1 · active not recruiting Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma · 722 trials list this drug (132 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07601100Phase 1/Phase 2 · not yet recruiting Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05900882Phase 2 · completed SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05272826Phase 2 · recruiting Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07793422Phase 3 · not yet recruiting Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06158841Phase 3 · active not recruiting Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04626791Phase 2 · active not recruiting Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma · 722 trials list this drug (132 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227311Phase 2 · recruiting A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06152575Phase 3 · recruiting MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04151667Phase 2 · completed Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02220049Phase 1 · completed Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04566328Phase 3 · recruiting Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00720785Phase 1 · completed Natural Killer Cells and Bortezomib to Treat Cancer · 722 trials list this drug (132 active) | — | — | Multiple Myeloma,Chronic Myeloid Leukemia, BCR-ABL1 Positive,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07285239Phase 3 · recruiting Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07341867Phase 1 · recruiting Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype · 722 trials list this drug (132 active) | — | — | Multiple Myeloma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07764978Phase 3 · recruiting Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07513129Phase 1 · recruiting Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma · 722 trials list this drug (132 active) | — | — | Lymphoma,T Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06918002Phase 3 · recruiting Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03136146Phase 2 · recruiting Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia · 722 trials list this drug (132 active) | — | — | Acute Lymphoblastic Leukemia,Burkitt Leukemia,Lymphoblastic Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06390319Phase 2 · recruiting Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) · 722 trials list this drug (132 active) | — | — | T Acute Lymphoblastic Leukemia,T-Cell Non-Hodgkin Lymphoma,Mixed Phenotype Acute Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07072585Phase 2/Phase 3 · not yet recruiting Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) · 722 trials list this drug (132 active) | — | — | T Lymphoblastic Leukemia/Lymphoma,T Acute Lymphoblastic Leukemia,T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00644228Phase 3 · active not recruiting Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02112916Phase 3 · active not recruiting Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma · 722 trials list this drug (132 active) | — | — | Childhood T Acute Lymphoblastic Leukemia,Adult T Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06413498Phase 3 · active not recruiting A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04140162Phase 2 · active not recruiting Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07008638Phase 1/Phase 2 · recruiting Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) · 722 trials list this drug (132 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07224672Phase 2 · recruiting A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis · 722 trials list this drug (132 active) | — | — | Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02343042Phase 1/Phase 2 · recruiting Selinexor and Backbone Treatments of Multiple Myeloma Patients · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04754945Phase 1 · active not recruiting Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis · 722 trials list this drug (132 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05137054Phase 1 · recruiting A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06029998Phase 2 · active not recruiting Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion · 722 trials list this drug (132 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06192979NA · recruiting Optimize First-line Treatment for AL Amyloidosis With t (11; 14) · 722 trials list this drug (132 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06083922Phase 2 · recruiting A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma,Monoclonal Gammopathy of Renal Significance | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04775550Phase 2 · active not recruiting DARA RVD For High Risk SMM · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07671287Phase 3 · not yet recruiting GMMG-HD11/DSMM XXI/64007957MMY3010 · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05558319Phase 3 · recruiting NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02553460Phase 1/Phase 2 · active not recruiting Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I · 722 trials list this drug (132 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068597Phase 1/Phase 2 · recruiting Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies · 722 trials list this drug (132 active) | — | — | Multiple Myeloma,Non-Hodgkin Lymphoma,Acute Myeloid Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07614360Phase 2 · not yet recruiting Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07637526not yet recruiting Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07247097Phase 2 · not yet recruiting ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07663253recruiting Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03651128Phase 3 · completed Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07428369Phase 2/Phase 3 · withdrawn A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03117751Phase 2/Phase 3 · active not recruiting Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma · 722 trials list this drug (132 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04484623Phase 3 · active not recruiting Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06956170Phase 3 · active not recruiting All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05561387Phase 3 · recruiting Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06348147Phase 2 · withdrawn Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07635511Phase 3 · not yet recruiting Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies · 722 trials list this drug (132 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07018050Phase 2 · recruiting Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01415752Phase 2 · active not recruiting Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma · 722 trials list this drug (132 active) | — | — | Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05736419Phase 2 · recruiting A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05848687Phase 1/Phase 2 · recruiting TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II · 722 trials list this drug (132 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01371981Phase 3 · completed Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia · 722 trials list this drug (132 active) | — | — | Myeloid Neoplasm,Myeloid Sarcoma,Leukemia Cutis+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03652064Phase 3 · completed A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07609706Phase 1 · not yet recruiting A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00869232Phase 2 · active not recruiting UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00183937Phase 2 · terminated Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer · 722 trials list this drug (132 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01009840Phase 2 · completed IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05514990Phase 1/Phase 2 · active not recruiting Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00871013Phase 2 · active not recruiting Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05849610Phase 2 · active not recruiting Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06022939Phase 3 · recruiting Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis · 722 trials list this drug (132 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03319667Phase 3 · active not recruiting A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04653246Phase 2 · active not recruiting Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01668719Phase 1/Phase 2 · completed S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02783625Phase 1 · completed Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas · 722 trials list this drug (132 active) | — | — | Lymphoma,T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04246047Phase 3 · active not recruiting Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868654Phase 3 · active not recruiting China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868667Phase 3 · active not recruiting Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05392946Phase 1/Phase 2 · active not recruiting Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04166565Phase 2 · active not recruiting Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease · 722 trials list this drug (132 active) | — | — | Multiple Myeloma,Extraosseous Plasmacytoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04996160Phase 1 · completed Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia · 722 trials list this drug (132 active) | — | — | Acute Lymphoblastic Leukemia,Childhood Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00479128Phase 1 · active not recruiting Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors · 722 trials list this drug (132 active) | — | — | Solid Neoplasm,Malignant Urethral Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02719613Phase 2 · completed Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03763162Phase 2 · active not recruiting Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05572515Phase 3 · active not recruiting A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03984097Phase 1 · completed A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04433156Phase 2 · completed VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma · 722 trials list this drug (132 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04975997Phase 3 · active not recruiting Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00428142Phase 2 · completed Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma · 722 trials list this drug (132 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01453088Phase 2 · terminated Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04268498Phase 2 · active not recruiting A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02773030Phase 1/Phase 2 · active not recruiting A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03590171Phase 2 · recruiting International Study for Treatment of High Risk Childhood Relapsed ALL 2010 · 722 trials list this drug (132 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05257083Phase 3 · active not recruiting A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06353022Phase 2 · active not recruiting Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00492050Phase 2 · active not recruiting Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia · 722 trials list this drug (132 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06627309recruiting Rapid dFLC Response Predict CHR in AL Amyloidosis · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802356Phase 2 · active not recruiting Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03729804Phase 3 · active not recruiting Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01919086Phase 2 · completed Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03589222Phase 2 · active not recruiting SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00378105Phase 1/Phase 2 · active not recruiting Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03850366Phase 2 · recruiting HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib · 722 trials list this drug (132 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05804032Phase 3 · completed Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02844322Phase 4 · completed The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia · 722 trials list this drug (132 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03710603Phase 3 · active not recruiting Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04751877Phase 3 · active not recruiting Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00572169Phase 3 · active not recruiting UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03617731Phase 3 · active not recruiting Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04414475Phase 2 · recruiting A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04285268Phase 2 · withdrawn Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 722 trials list this drug (132 active) | — | — | Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05556616Phase 1 · terminated A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07297329Phase 3 · recruiting A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04240054Phase 2 · recruiting Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01208662Phase 3 · active not recruiting Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02718833Phase 2 · active not recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02312102Phase 1 · completed Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation · 722 trials list this drug (132 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04392648Phase 1 · withdrawn A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02441686Phase 2 · completed Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05695508Phase 2 · recruiting GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04268199Phase 2 · recruiting A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment · 722 trials list this drug (132 active) | — | — | Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03829371Phase 4 · active not recruiting STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04091126Phase 1 · active not recruiting Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01286272Phase 2 · completed Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma · 722 trials list this drug (132 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07200583completed Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients · 722 trials list this drug (132 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00310037Phase 2 · completed Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma · 722 trials list this drug (132 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564052Phase 2 · completed A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma · 722 trials list this drug (132 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01241708Phase 3 · completed Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01863550Phase 3 · active not recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02136134Phase 3 · completed Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02195479Phase 3 · completed A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05163405completed Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma. · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03828292Phase 1 · completed An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03314181Phase 2 · active not recruiting A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07045909Phase 2 · recruiting Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04052880Phase 2 · active not recruiting Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06464991Phase 3 · recruiting A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05123131Phase 2 · active not recruiting Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04570631Phase 1 · terminated Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06034561Phase 2 · recruiting Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia · 722 trials list this drug (132 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00329589Phase 1 · completed A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients · 722 trials list this drug (132 active) | — | — | Central Nervous System Neoplasm,Malignant Head and Neck Neoplasm,Malignant Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04892446Phase 2 · terminated Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02224729Phase 2 · completed Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412565Phase 2 · completed A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01998971Phase 1 · completed A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06140966Phase 2 · recruiting Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03643276Phase 3 · recruiting Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 · 722 trials list this drug (132 active) | — | — | Childhood Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06900647Phase 1 · recruiting Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer · 722 trials list this drug (132 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03844360Phase 4 · recruiting Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease · 722 trials list this drug (132 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02555839completed Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01163357Phase 1 · completed Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03544281Phase 1/Phase 2 · completed To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04717700Phase 2 · active not recruiting Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06853080Phase 2 · active not recruiting Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid Tumors · 722 trials list this drug (132 active) | — | — | Rhabdoid Tumor,Atypical Teratoid/Rhabdoid Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01539083Phase 3 · completed Velcade (Bortezomib) Consolidation After Transplant · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02874742Phase 2 · completed Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06572813Phase 1/Phase 2 · recruiting Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer · 722 trials list this drug (132 active) | — | — | Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06342466Phase 2 · recruiting Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665140Phase 2/Phase 3 · recruiting Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03989414Phase 1/Phase 2 · active not recruiting A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02057380Phase 2 · completed A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial · 722 trials list this drug (132 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06656221Phase 2 · not yet recruiting A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma · 722 trials list this drug (132 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06284395recruiting Two Schemes Response in Multiple Myeloma · 722 trials list this drug (132 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02375555Phase 2 · completed Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01827137Phase 1/Phase 2 · completed WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03000634Phase 2 · withdrawn 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03829020Phase 1 · completed Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03110562Phase 3 · completed Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01183949Phase 1/Phase 2 · completed Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06505369Phase 2 · recruiting Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02654990Phase 2 · completed Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04352205Phase 2 · terminated Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03942224Phase 2 · unknown Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05422027Phase 1/Phase 2 · unknown Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04956302Phase 1 · terminated Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05248633Phase 2 · recruiting Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma · 722 trials list this drug (132 active) | — | — | Solitary Plasmacytoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03234972Phase 3 · completed A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03188172Phase 2 · unknown MUK Nine b: OPTIMUM Treatment Protocol · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05895201Phase 1/Phase 2 · withdrawn High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD · 722 trials list this drug (132 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia,Adult Acute Lymphoblastic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01063907Phase 1/Phase 2 · completed A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03217812Phase 3 · completed A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06189833Phase 2 · unknown Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00863369Phase 1/Phase 2 · completed Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma · 722 trials list this drug (132 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 722 trials list this drug (132 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04912427Phase 1 · terminated Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease · 722 trials list this drug (132 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |